Phenotype and Treatment of Chronic Obstructive Pulmonary Disease
Yuanlin Song,Chen Wang
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20141919
IF: 6.133
2014-01-01
Chinese Medical Journal
Abstract:Chronic obstructive pulmonary disease (COPD) is the most common chronic airway disease affecting Chinese population and it ranks number four leading cause of death. The high mortality and morbidity, increased prevalence, significant loss of labor, and high medical expenditure warrants attention from the health organization and society to standardize the diagnosis and treatment of COPD. Overall COPD treatment efficacy has been significantly improved with application of long activating bronchial dilator (LABD), due to the imbalance and geographically different distribution of medical resource and education, standardized treatment under COPD guideline remain the major protocol in a long time period in the future. COPD is a disease with heterogeneity, such as different profile on clinical symptom, treatment response, and different prognosis. The mechanism of this nature of heterogeneity is due to the complexity of environment exposure and genetic background. It is because of the complicated airway antigen and toxicant exposure, the different inflammation response after exogenous stimulant, the complex metabolism and medical treatment response, COPD patients present far more versatile and heterogeneous phenotypes than other airway disease. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is the major guideline for diagnosis and treatment of COPD worldwide based on lung function measurement, life quality assessment, and risk factor evaluation for acute exacerbation.1 All patients could be classified into A, B, C, and D groups, then receive different regimen according to recommendation level. When reviewing several major global clinical trials, patients from same GOLD group showed very different treatment response and outcomes.2 It is therefore important to have more proper patient subclassification and select right population and medicine for more specific treatment. In this issue, Dr. Xie et al3 showed group classification based on pulmonary function correlated with hospitalization. The above correlation with modified British Medical Research Council grade=1 as the cut off threshold was better than that with the cutoff threshold at 2. These evidences suggested there was some gap between guideline and clinical practice in real world. It is useful to understand these differences in order to dissect the true meaning of heterogeneity. Those phenomena suggested the necessity of having a tailored process of COPD diagnosis and treatment under guideline. The study on COPD phenotype provided data and evidence for more specific and targeted therapy. COPD phenotype has been defined as “a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes”.4 Phenotype based therapy should have a more specific target population with maximum treatment response or good correlation with prognosis. COPD phenotype includes but not limited to asthma-COPD overlap syndrome, bronchitis type, emphysemahyperinflation type and frequent exacerbation type. The guideline from Spanish Society of Pneumology and Thoracic Surgery and Czech Pneumological and Physiological Society provided specific treatment regimen based on phenotype.5,6 Those guidelines together with GOLD enriched the strategy of COPD diagnosis and treatment. Although the GOLD may be more authorative given high level of clinical evidence and global advisory board, the indication of COPD treatment was rather more general, while the guideline from Spanish and Czech was more specific and personalized. These guidelines were compensated to each other. The major difference of GOLD and phenotype-based therapy was the application of inhaled corticosteroid (ICS) and phosphodiesterase type 4 (PDE4) inhibitor, etc. For patient who has asthma-COPD overlap syndrome, ICS plus long-acting beta-agonist (LABA) are recommended no matter which group the patients belong to according to GOLD. It is known that overlap syndrome does exist in both A or B groups and adding tiotropium could further improve lung function besides ICS+LABA. Bronchitis phenotype indicates that for the patients who have recurrent cough with sputum, dyspnea after exertion, cyanosis on lips etc., the regimen include ICS+LABA, longacting muscarinic antagonist (LAMA) or triple therapy, PDE4 inhibitor and mucoactive medicine. Emphysemahyperinflation phenotype indicates dyspnea after exertion, with clear lung emphysema or bulle on CT scanning. Patients who were classified in this group usually have poor response to ICS and PDE4 inhibitor, while LABA, LAMA or LABA+LAMA, or surgical therapy is recommended. Those patients who have frequent acute exacerbation are suitable for adding ICS. Our unpublished data also suggested high level cytokines in blood suggest good response from adding ICS. A series of clinical parameters have been used to better define and evaluate COPD, such as gender, age, body mass index, bronchial dilator response, fraction of exhaled nitric oxide (FENO), airway esinophils/neutrophils cell count, life quantity score, CT scanning, 6-minute walk, lung function test, symptom, etc. The three parameters of forced expiratory volume in one second (FEV1), COPD assessment test /modified British Medical Research Council questionnaire /clinical COPD questionnaire, acute exacerbation have been used as major criteria for COPD evaluation by GOLD but other parameters stated above may help to define COPD phenotype and more precise and comprehensive treatment regimen, as well as prognosis. Besides above phenotypes, COPD combined with bronchioectasis might be a new COPD phenotype although the exact treatment strategy has not been universally accepted. Those patients may benefit from adding mucoactive medicine, macrolides, and proper antibiotic use besides LABD. The doubled mortality of COPD combining with bronchioectasis compared with COPD alone strongly suggests high demanding to this group of patients. In this issue, Dr. Wang et al7 found a high occurrence rate of COPD in type 2 diabetic patients, while disease progression was much faster in COPD patient once they had diabetes. All these data suggested possibly new COPD phenotypes and treatment regimen based on phenotypes classification. Of note, COPD treatment based on phenotypes is compliment to GOLD with more specific and tailored plan, it is essential to test the strategy in clinical practice and to improve COPD management with more data support.